NDA 021464 · Pfizer
Vfend
Voriconazole · Oral, Injection
Last checked: Nov 19, 2026Latest source record: Nov 14, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Nov 14, 2003
Approved uses
1
Original approval plus efficacy supplements
Registered trials
153
39 Phase 3, 14 recruiting
FAERS reports
30,722
28,342 serious, 8,951 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- VFEND · VORICONAZOLE 200MG · Tablet, Oral · Prescription
- VFEND · VORICONAZOLE 200MG · Injectable, Injection · Prescription
- VFEND · VORICONAZOLE 50MG · Tablet, Oral · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Voriconazole" as an intervention, any sponsor and status, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
Sumitomo Pharma America, Inc.Industry
NCT04988555 · 606 participants (planned) · Start Feb 28, 2022 · Primary completion Jun 30, 2027
Drug: Enzomenib; azoles and 4 more · For: Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Acute; Multiple Myeloma and 1 more
Sites: Newport Beach, California; Palo Alto, California; Denver, Colorado · 104 sites in all
- Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)Pivotal-lookingCompleted
Medical College of WisconsinAcademic, hospital or other
NCT00075803 · 600 participants · Start Nov 2003 · Primary completion Sep 2006
Drug: Fluconazole; Voriconazole · For: Lymphoma; Infection; Leukemia
Sites: Birmingham, Alabama; La Jolla, California; Stanford, California · 33 sites in all
- A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01782131 · 585 participants · Start Sep 25, 2013 · Primary completion Jul 10, 2019
Drug: Posaconazole; Voriconazole and 1 more · For: Fungal Infections; Invasive Pulmonary Aspergillosis
- Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without DiabetesPivotal-lookingActive, not recruiting
OrsoBio, IncIndustry
NCT05822544 · 564 participants (planned) · Start Apr 22, 2023 · Primary completion Sep 2026
Drug: TLC-6740 Oral Solution; TLC-6740 Tablet and 2 more · For: Healthy Subjects; Obesity; Type 2 Diabetes
Sites: Auckland, New Zealand; Christchurch, New Zealand · 4 sites in all
- Isavuconazole (BAL8557) for Primary Treatment of Invasive AspergillosisPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00412893 · 527 participants · Start Mar 7, 2007 · Primary completion Mar 28, 2013
Drug: Isavuconazole; Voriconazole · For: Aspergillosis; Invasive Fungal Infection
Sites: Birmingham, Alabama; San Francisco, California; Chicago, Illinois · 107 sites in all
- Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00289991 · 489 participants · Start Mar 2006 · Primary completion Feb 2009
Drug: Itraconazole; Vfend - voriconazole · For: Antifungal Prophylaxis of Invasive Fungal Infections
Sites: Vancouver, Canada; Winnipeg, Canada; Hamilton, Canada · 49 sites in all
- Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive AspergillosisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00531479 · 459 participants · Start Jul 2008 · Primary completion Apr 2011
Drug: voriconazole; anidulafungin and 1 more · For: Aspergillosis
Sites: Birmingham, Alabama; Little Rock, Arkansas; La Jolla, California · 107 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,336
- off label use2,510
- drug interaction2,408
- death1,481
- pyrexia1,455
- pneumonia1,359
- condition aggravated1,157
- bronchopulmonary aspergillosis1,066
- aspergillus infection943
- febrile neutropenia924
- respiratory failure865
- nausea796
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 315 |
| 2005 | 322 |
| 2006 | 418 |
| 2007 | 446 |
| 2008 | 429 |
| 2009 | 618 |
| 2010 | 855 |
| 2011 | 876 |
| 2012 | 1,097 |
| 2013 | 1,062 |
| 2014 | 1,063 |
| 2015 | 1,201 |
| 2016 | 1,422 |
| 2017 | 1,997 |
| 2018 | 2,244 |
| 2019 | 2,497 |
| 2020 | 2,370 |
| 2021 | 2,184 |
| 2022 | 2,258 |
| 2023 | 1,992 |
| 2024 | 1,898 |
| 2025 | 1,869 |
| 2026 | 1,288 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vfend (Voriconazole)
2024 spending
$8K
Beneficiaries
12
19 claims
Per beneficiary
$635
$4.41 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $42,158 |
| 2021 | $13,420 |
| 2022 | $8,554 |
| 2023 | $10,102 |
| 2024 | $7,623 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA, Raad II, Marr KA, et al. · Lancet 2016 · Clinical Trial, Phase III, Comparative Study
- Interactions between herbal medicines and prescribed drugs: an updated systematic review.
Izzo AA, Ernst E · Drugs 2009 · Systematic Review
- Candida auris-a systematic review to inform the world health organization fungal priority pathogens list.
Kim HY, Nguyen TA, Kidd S, et al. · Med Mycol 2024 · Systematic Review
- Combination antifungal therapy for invasive aspergillosis: a randomized trial.
Marr KA, Schlamm HT, Herbrecht R, et al. · Ann Intern Med 2015 · Multicenter Study, Randomized Controlled Trial
- Cryptococcosis-a systematic review to inform the World Health Organization Fungal Priority Pathogens List.
Dao A, Kim HY, Garnham K, et al. · Med Mycol 2024 · Systematic Review
- Histoplasmosis: A systematic review to inform the World Health Organization of a fungal priority pathogens list.
Dao A, Kim HY, Halliday CL, et al. · Med Mycol 2024 · Systematic Review
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.